110 related articles for article (PubMed ID: 19211775)
1. Identification of iNOS inhibitors using InteraX.
Mallinder PR; Wallace AV; Allenby G
J Biomol Screen; 2009 Mar; 14(3):263-72. PubMed ID: 19211775
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the InteraX system technology in a high-throughput screening environment.
Büttner FH; Kumpf R; Menzel S; Reulle D; Valler MJ
J Biomol Screen; 2005 Aug; 10(5):485-94. PubMed ID: 16093558
[TBL] [Abstract][Full Text] [Related]
3. Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models.
Bonnefous C; Payne JE; Roppe J; Zhuang H; Chen X; Symons KT; Nguyen PM; Sablad M; Rozenkrants N; Zhang Y; Wang L; Severance D; Walsh JP; Yazdani N; Shiau AK; Noble SA; Rix P; Rao TS; Hassig CA; Smith ND
J Med Chem; 2009 May; 52(9):3047-62. PubMed ID: 19374401
[TBL] [Abstract][Full Text] [Related]
4. Cell-based high-throughput screening assay system for monitoring G protein-coupled receptor activation using beta-galactosidase enzyme complementation technology.
Yan YX; Boldt-Houle DM; Tillotson BP; Gee MA; D'Eon BJ; Chang XJ; Olesen CE; Palmer MA
J Biomol Screen; 2002 Oct; 7(5):451-9. PubMed ID: 14599361
[TBL] [Abstract][Full Text] [Related]
5. KLYP956 is a non-imidazole-based orally active inhibitor of nitric-oxide synthase dimerization.
Symons KT; Massari ME; Nguyen PM; Lee TT; Roppe J; Bonnefous C; Payne JE; Smith ND; Noble SA; Sablad M; Rozenkrants N; Zhang Y; Rao TS; Shiau AK; Hassig CA
Mol Pharmacol; 2009 Jul; 76(1):153-62. PubMed ID: 19364813
[TBL] [Abstract][Full Text] [Related]
6. A high-throughput, nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP).
Vainshtein I; Silveria S; Kaul P; Rouhani R; Eglen RM; Wang J
J Biomol Screen; 2002 Dec; 7(6):507-14. PubMed ID: 14599348
[TBL] [Abstract][Full Text] [Related]
7. Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS dimerization inhibitors that are orally active in pain models.
Payne JE; Bonnefous C; Symons KT; Nguyen PM; Sablad M; Rozenkrants N; Zhang Y; Wang L; Yazdani N; Shiau AK; Noble SA; Rix P; Rao TS; Hassig CA; Smith ND
J Med Chem; 2010 Nov; 53(21):7739-55. PubMed ID: 20931971
[TBL] [Abstract][Full Text] [Related]
8. The novel imidazopyridine 2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) is a highly selective inhibitor of the inducible nitric-oxide synthase.
Strub A; Ulrich WR; Hesslinger C; Eltze M; Fuchss T; Strassner J; Strand S; Lehner MD; Boer R
Mol Pharmacol; 2006 Jan; 69(1):328-37. PubMed ID: 16223957
[TBL] [Abstract][Full Text] [Related]
9. Phenylpyrrole derivatives as neural and inducible nitric oxide synthase (nNOS and iNOS) inhibitors.
López Cara LC; Camacho ME; Carrión MD; Tapias V; Gallo MA; Escames G; Acuña-Castroviejo D; Espinosa A; Entrena A
Eur J Med Chem; 2009 Jun; 44(6):2655-66. PubMed ID: 19117642
[TBL] [Abstract][Full Text] [Related]
10. Cyclo(dehydrohistidyl-l-tryptophyl) inhibits nitric oxide production by preventing the dimerization of inducible nitric oxide synthase.
Sohn MJ; Hur GM; Byun HS; Kim WG
Biochem Pharmacol; 2008 Feb; 75(4):923-30. PubMed ID: 18061143
[TBL] [Abstract][Full Text] [Related]
11. BYK191023 (2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3h-imidazo[4,5-b]pyridine) is an NADPH- and time-dependent irreversible inhibitor of inducible nitric-oxide synthase.
Tiso M; Strub A; Hesslinger C; Kenney CT; Boer R; Stuehr DJ
Mol Pharmacol; 2008 Apr; 73(4):1244-53. PubMed ID: 18178668
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a series of aminopiperidines as novel iNOS inhibitors.
Le Bourdonnec B; Leister LK; Ajello CA; Cassel JA; Seida PR; O'Hare H; Gu M; Chu GH; Tuthill PA; DeHaven RN; Dolle RE
Bioorg Med Chem Lett; 2008 Jan; 18(1):336-43. PubMed ID: 18024030
[TBL] [Abstract][Full Text] [Related]
13. 1-(1,3-Benzodioxol-5-ylmethyl)-3-[4-(1H-imidazol-1-yl)phenoxy]-piperidine analogs as potent and selective inhibitors of nitric oxide formation.
Wei RG; Adler M; Davey D; Ho E; Mohan R; Polokoff M; Tseng JL; Whitlow M; Xu W; Yuan S; Phillips G
Bioorg Med Chem Lett; 2007 May; 17(9):2499-504. PubMed ID: 17368901
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors.
Davey DD; Adler M; Arnaiz D; Eagen K; Erickson S; Guilford W; Kenrick M; Morrissey MM; Ohlmeyer M; Pan G; Paradkar VM; Parkinson J; Polokoff M; Saionz K; Santos C; Subramanyam B; Vergona R; Wei RG; Whitlow M; Ye B; Zhao ZS; Devlin JJ; Phillips G
J Med Chem; 2007 Mar; 50(6):1146-57. PubMed ID: 17315988
[TBL] [Abstract][Full Text] [Related]
15. The rational design of inhibitors of nitric oxide formation by inducible nitric oxide synthase.
Whitlow M; Adler M; Davey D; Huang Q; Koovakkat S; Parkinson JF; Pham E; Polokoff M; Xu W; Yuan S; Phillips G
Bioorg Med Chem Lett; 2007 May; 17(9):2505-8. PubMed ID: 17336523
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and characterization of a novel class of coumarin-based inhibitors of inducible nitric oxide synthase.
Jackson SA; Sahni S; Lee L; Luo Y; Nieduzak TR; Liang G; Chiang Y; Collar N; Fink D; He W; Laoui A; Merrill J; Boffey R; Crackett P; Rees B; Wong M; Guilloteau JP; Mathieu M; Rebello SS
Bioorg Med Chem; 2005 Apr; 13(8):2723-39. PubMed ID: 15781384
[TBL] [Abstract][Full Text] [Related]
17. Identification of a flavin mononucleotide module residue critical for activity of inducible nitrite oxide synthase.
Liu XD; Mazumdar T; Xu Y; Getzoff ED; Eissa NT
J Immunol; 2009 Nov; 183(9):5977-82. PubMed ID: 19828635
[TBL] [Abstract][Full Text] [Related]
18. The discovery of novel, potent and highly selective inhibitors of inducible nitric oxide synthase (iNOS).
Cheshire DR; Åberg A; Andersson GM; Andrews G; Beaton HG; Birkinshaw TN; Boughton-Smith N; Connolly S; Cook TR; Cooper A; Cooper SL; Cox D; Dixon J; Gensmantel N; Hamley PJ; Harrison R; Hartopp P; Käck H; Leeson PD; Luker T; Mete A; Millichip I; Nicholls DJ; Pimm AD; St-Gallay SA; Wallace AV
Bioorg Med Chem Lett; 2011 Apr; 21(8):2468-71. PubMed ID: 21398123
[TBL] [Abstract][Full Text] [Related]
19. Extensive ligand-based modeling and in silico screening reveal nanomolar inducible nitric oxide synthase (iNOS) inhibitors.
Suaifan GA; Shehadehh M; Al-Ijel H; Taha MO
J Mol Graph Model; 2012 Jul; 37():1-26. PubMed ID: 22609742
[TBL] [Abstract][Full Text] [Related]
20. Pyrazoles and pyrazolines as neural and inducible nitric oxide synthase (nNOS and iNOS) potential inhibitors (III).
Carrión MD; López Cara LC; Camacho ME; Tapias V; Escames G; Acuña-Castroviejo D; Espinosa A; Gallo MA; Entrena A
Eur J Med Chem; 2008 Nov; 43(11):2579-91. PubMed ID: 18325637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
